Innospec Reports Third Quarter 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Innospec Reports Third Quarter 2014 Financial Results

Revenues up 18 percent from last year with continued strong performance from acquisitions and core businesses

Favorable sales mix drives improved gross margins

27 percent increase in operating income and 38 percent increase in EBITDA

Adjusted non-GAAP diluted EPS of $0.77 in line with expectations; Strong cash flows, lower net debt position enhances balance sheet

Biannual dividend increased to $0.28 per share – total dividend for 2014 up 10 percent on prior year

ENGLEWOOD, Colo., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Innospec, Inc. (Nasdaq: IOSP ) today announced its financial results for the third quarter ended September 30, 2014. At the same time, the Company announced that it is declaring a biannual dividend of $0.28 per common share for the second half of 2014, which will be paid on November 26, 2014 to shareholders of record on November 17, 2014. This brings the annual dividend to 55 cents per share, a 10 percent increase on 2013.

Total net sales for the third quarter were $228.2 million, an 18 percent increase from $192.8 million in the corresponding period last year. Net income was $20.8 million, or $0.83 per diluted share, compared to $14.0 million, or $0.58 per diluted share, recorded a year ago. EBITDA (earnings before interest, taxes, depreciation, amortization and impairment) for the quarter was $32.6 million, a 38 percent increase from the $23.6 million posted in 2013's third quarter.

Results for this quarter include after-tax foreign currency exchange gains of $0.8 million, or $0.03 per diluted share, gains from adjustments to income tax provisions of $1.8 million, or $0.07 per diluted share, and after-tax acquisition related costs of $1.0 million, or $0.04 per diluted share. Excluding these items, adjusted non-GAAP EPS was $0.77 per diluted share, up from $0.65 per diluted share a year ago. Cash generation was again strong in the third quarter, with operating cash inflows of $25.2 million before capital expenditures during the quarter of $6.6 million. Innospec closed the quarter with a net debt position of $19.7 million.

EBITDA and net income excluding special items, and related per-share amounts, are non-GAAP financial measures that are defined and reconciled with GAAP results herein and in the schedules below.

  Quarter ended September 30, 2014 Quarter ended September 30, 2013
             
  Income     Income    
    before     before    
  income Net Diluted income Net Diluted
(in millions, except share and per share data)  taxes Income EPS taxes income EPS
             
Reported GAAP amounts  $ 25.4  $ 20.8  $ 0.83  $ 18.3  $ 14.0  $ 0.58
             
Adjustment of income tax provisions (1.8) (1.8) (0.07) 0.1 0.1 --
Acquisition-related costs 1.3 1.0 0.04 1.3 1.0 0.04
Foreign currency exchange (gains)/losses (1.0) (0.8) (0.03) 0.8 0.6 0.03
  (1.5) (1.6) (0.06) 2.2 1.7 0.07
             
Adjusted non-GAAP amounts  $ 23.9  $ 19.2  $ 0.77  $ 20.5  $ 15.7  $ 0.65

For the first nine months of 2014, total net sales of $670.2 million increased 16 percent from $577.2 million in the corresponding period last year.  Net income for the nine-month period was $56.2 million, or $2.26 per diluted share, compared with $49.1 million, or $2.04 per diluted share, a year ago.  Excluding special items, diluted earnings per share for the first nine months of 2014 were $2.08, broadly similar to the $2.12 reported a year ago.  EBITDA for the first nine months of 2014 was $91.3 million, 18 percent higher than $77.3 million a year ago.

Commenting on the third quarter results, Patrick S. Williams, President and Chief Executive Officer, said, "We have maintained good momentum through the third quarter of 2014, and we are generally very pleased with the performance of our core businesses, including our acquisitions.  In the face of challenging geopolitical issues and heightened competitive pressures, particularly in the EMEA (Europe, Middle East & Africa) region, Innospec continued to deliver on its targets of profitable top- and bottom-line growth.  We have also maintained a very strong balance sheet, and we continue to be cash-generative.

"Fuel Specialties revenues increased 14 percent year-over-year, principally driven by an exceptional performance by Oilfield Specialties, which more than offset an expected, weaker EMEA environment.  At the same time, our gross margins in Fuel Specialties improved as a result of the performance of Oilfield Specialties and a richer sales mix in our core business.  The performance was enhanced by a strong quarter for the AvTel product line, which we expect to normalize in the fourth quarter.

"Our Fuel Specialties business has continued to grow impressively throughout the Americas during the third quarter, with strong contributions from both our Fuels and our Oilfield Specialties businesses.  In spite of a continued weak EMEA economy, impacted by lower volumes and refinery activity, as well as heightened pricing pressures, we have maintained our market position.  As we reported previously, government sanctions related to Russia and Ukraine continue to negatively impact our sales in this region.  We are encouraged by our third quarter improvement and new business growth in our Asia- Pacific operations.

"Our Oilfield Specialties business started to perform, and showed good progress during the third quarter.  On October 1, 2014 we announced the intended acquisition of Independence Oilfield Chemicals, LLC ("Independence").  The transaction was cleared through a successful Hart Scott Rodino filing, and the acquisition was completed on October 27, 2014.  Independence serves the oil and gas industries, with a focus on completion, stimulation and production chemicals and with annualized sales of approximately $150 million.  Importantly, we now have a presence in most of the major energy basins in the U.S."

"In Performance Chemicals, we delivered 19 percent year-over-year growth.  This was driven by a mixture of a strong new product pipeline and a good contribution from our personal care acquisitions.  The margin in this business is 24 percent, driven by our Personal Care segment, which is the strategic focus.  We continue to be excited by the quality of new products delivered by our R&D team."

Net sales in Fuel Specialties for the third quarter were $156.1 million, up 14 percent from the $137.4 million reported in last year's third quarter, driven by sales growth in the Americas and a solid contribution from Oilfield Specialties.  Excluding the acquisition, volumes reduced by 8 percent partially offset by a 5 percent richer sales mix. Revenues improved 4 percent in the Americas due to a richer sales mix while in EMEA, sales fell 12 percent from a strong performance in the comparative quarter, driven by lower volumes impacted by ongoing trading constraints in Russia and Ukraine.  Sales in Asia-Pacific fell by 3 percent compared to prior year, but underlying sales, discounting the previously-reported contract loss, continued to grow to plan at 9 percent during the third quarter.  The segment's gross margin was 34.1 percent, up from 31.0 percent a year ago primarily driven by higher margin contributions from Oilfield Specialties and AvTel sales.  Operating income for the quarter was $24.5 million, up from $22.3 million a year ago.

In Performance Chemicals, net sales increased 19 percent, to $57.0 million, as acquisition growth contributed 11 percent to revenues.  Underlying volumes grew by 5 percent, driven by the Personal Care business, and there was a 3 percent favorable currency impact.  By region, sales increased 30 percent in the Americas, 6 percent in EMEA and by 22 percent in Asia-Pacific.  Performance Chemicals' gross margin was 24.0 percent, up slightly from 23.2 percent a year ago.  The segment's operating income was $6.6 million, an 18 percent increase from last year's $5.6 million.

Octane Additives' net sales for the quarter were $15.1 million, more than double the $7.5 million a year ago.  The segment's gross margin was 44.4 percent, compared to 49.3 percent in last year's third quarter.  Operating income for the quarter was $4.9 million, up significantly from $2.1 million in the corresponding period a year ago.  This is in line with our expectations as the business continued to rely on sales to a single end use customer.

Corporate costs for the quarter were $10.0 million compared with $9.4 million a year ago.  The increase was primarily driven by $0.9 million of amortization related to the implementation of the company-wide information management system.  As expected the quarterly pension charge was $0.8 million in the quarter.  The third quarter's effective tax rate is 18 percent, and the full year adjusted effective tax rate is anticipated to be 23 percent.

Net cash generated from operations in the quarter was $25.2 million driven by a strong trading performance.  As of September 30, 2014, Innospec had $95.3 million in cash, cash equivalents and short-term investments, and total debt of $115.0 million.

Mr. Williams concluded, "With our core businesses very much on track and with our acquisitions now starting to perform, we believe that Innospec is in a very strong position for continued success over the intermediate term. We are comfortable with our positioning in the Oilfield Specialties area, as we focus on integrating Independence into the Innospec global network.  This latest acquisition takes our Oilfield Specialties business to an annualized revenue run rate of more than $240 million.  The business is very complementary to our existing Oilfield Specialties business, both in terms of technology and geographical footprint and brought us an exceptional management team.  We are excited to be in a positive position in such a dynamic market.

"While we are focused on integration and growth, we will continue to be alert to acquisition opportunities that fit our model, particularly in the Personal Care space.

"Our continued, strong cash generation at Innospec gives us the flexibility to invest in our core businesses and pursue selected acquisition opportunities, while at the same time balancing other forms of capital management.  I am pleased that we have been able to increase our biannual dividend to 28 cents, making a total for the year of 55 cents – which represents a 10 percent increase over the 2013 payments. We expect to continue to pursue our share buyback program on an opportunistic basis, as we seek to enhance returns to our investors."

Use of Non-GAAP Financial Measures

The information presented in this press release includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise EBITDA, income before income taxes excluding special items and net income excluding special items and related per share amounts. EBITDA is net income per our consolidated financial statements adjusted for the exclusion of charges for interest expense, net, income taxes, depreciation, amortization and impairment of Octane Additives segment goodwill. Income before income taxes, net income and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of adjustment of income tax provisions, acquisition-related costs and foreign currency exchange (gains)/losses. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the schedules below. The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company's underlying performance and identifying operating trends. In addition, management uses these non-GAAP financial measures internally to allocate resources and evaluate the performance of the Company's operations. While the Company believes that such measures are useful in evaluating the Company's performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly-titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company's performance relative to other companies in similar industries. Management believes the most directly comparable GAAP financial measure is GAAP net income and has provided a reconciliation of EBITDA and net income excluding special items, and related per share amounts, to GAAP net income herein and in the schedules below.

About Innospec Inc.

Innospec Inc. is an international specialty chemicals company with approximately 1300 employees in 20 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific.  The Fuel Specialties business specializes in manufacturing and supplying the fuel additives that help improve fuel efficiency, boost engine performance and reduce harmful emissions.  This business also contains Oilfield Specialties which provides specialty chemicals for oil & gas drilling and production operations.  Innospec's Performance Chemicals business provides effective technology-based solutions for our customers' processes or products focused in the Personal Care; Polymers; and Fragrance Ingredients markets. Innospec's Octane Additives business is the world's only producer of tetra ethyl lead.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements.  Such forward-looking statements include statements (covered by words like "expects," "estimates," "anticipates," "may," "believes" or similar words or expressions), for example, which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors" in such reports.  Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Schedule 1
         
INNOSPEC INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
         
  Three Months Ended  Nine Months Ended
    September 30 September 30
(in millions, except share and per share data) 2014 2013 2014 2013
         
Net sales  $ 228.2  $ 192.8  $ 670.2  $ 577.2
Cost of goods sold (154.6) (135.4) (462.3) (396.6)
Gross profit 73.6 57.4 207.9 180.6
         
Operating expenses:        
Selling, general and administrative (42.4) (31.8) (122.1) (99.0)
Research and development (6.0) (5.7) (17.3) (16.6)
Impairment of Octane Additives segment goodwill -- (0.4) -- (1.0)
Total operating expenses (48.4) (37.9) (139.4) (116.6)
Operating income 25.2 19.5 68.5 64.0
Other net income/(expense) 1.0 (0.8) 2.2 (0.8)
Interest expense, net (0.8) (0.4) (2.5) (1.1)
Income before income taxes 25.4 18.3 68.2 62.1
Income taxes (4.6) (4.3) (12.0) (13.0)
Net income $ 20.8 $ 14.0 $ 56.2 $ 49.1
         
Earnings per share:        
Basic  $ 0.85  $ 0.59  $ 2.30  $ 2.09
Diluted  $ 0.83  $ 0.58  $ 2.26  $ 2.04
         
Weighted average shares outstanding (in thousands):        
Basic 24,420 23,621 24,394 23,518
Diluted 24,915 24,096 24,849 24,085
         
         
INNOSPEC INC. AND SUBSIDIARIES
Schedule 2A
         
SEGMENTAL ANALYSIS OF RESULTS Three Months Ended Nine Months Ended
  September 30 September 30
(in millions) 2014 2013 2014 2013
         
Net sales:        
Fuel Specialties  $ 156.1  $ 137.4  $ 465.4  $ 403.6
Performance Chemicals 57.0 47.9 172.5 140.2
Octane Additives 15.1 7.5 32.3 33.4
  228.2 192.8 670.2 577.2
         
Gross profit:        
Fuel Specialties 53.2 42.6 149.1 130.1
Performance Chemicals 13.7 11.1 42.6 32.9
Octane Additives 6.7 3.7 16.2 17.6
  73.6 57.4 207.9 180.6
         
Operating income:        
Fuel Specialties 24.5 22.3 67.8 66.4
Performance Chemicals 6.6 5.6 20.9 17.1
Octane Additives 4.9 2.1 12.0 13.0
Pension charge (0.8) (0.7) (2.5) (2.1)
Corporate costs (10.0) (9.4) (29.7) (29.4)
  25.2 19.9 68.5 65.0
         
Impairment of Octane Additives segment goodwill -- (0.4) -- (1.0)
Total operating income  $ 25.2  $ 19.5  $ 68.5  $ 64.0
         
         
Schedule 2B
         
NON-GAAP MEASURES Three Months Ended Nine Months Ended
   September 30 September 30
(in millions) 2014 2013 2014 2013
         
Net income  $ 20.8  $ 14.0  $ 56.2  $ 49.1
Interest expense, net 0.8 0.4 2.5 1.1
Income taxes 4.6 4.3 12.0 13.0
Depreciation and amortization 6.4 4.5 20.6 13.1
Impairment of Octane Additives segment goodwill -- 0.4 -- 1.0
EBITDA 32.6 23.6 91.3 77.3
         
Fuel Specialties 27.4 24.4 77.2 72.9
Performance Chemicals 8.6 7.1 27.4 21.0
Octane Additives 5.0 2.4 12.3 14.0
Pension charge (0.8) (0.7) (2.5) (2.1)
Corporate costs (8.6) (8.8) (25.3) (27.7)
  31.6 24.4 89.1 78.1
Other net income/(expense) 1.0 (0.8) 2.2 (0.8)
EBITDA  $ 32.6  $ 23.6  $ 91.3  $ 77.3
         
         
Schedule 3
INNOSPEC INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
     
  September 30, December 31,
(in millions) 2014 2013
     
Assets    
     
Current assets:    
Cash and cash equivalents  $ 90.4  $ 80.2
Short-term investments 4.9 6.6
Trade and other accounts receivable 117.3 135.8
Inventories 171.9 158.9
Current portion of deferred tax assets 8.7 8.7
Prepaid expenses 3.8 5.8
Prepaid income taxes 0.6 11.4
Total current assets 397.6 407.4
     
Property, plant and equipment 60.7 60.4
Goodwill 187.9 187.9
Other intangible assets 120.2 126.8
Deferred finance costs 1.3 1.8
Deferred tax assets, net of current portion 6.1 8.6
Other non-current assets 0.8 1.8
Total assets  $ 774.6  $ 794.7
     
Liabilities and Stockholders' Equity    
     
Current liabilities:    
Accounts payable  $ 51.8  $ 63.3
Accrued liabilities 65.3 73.5
Current portion of long-term debt -- 5.3
Current portion of plant closure provisions 4.1 6.2
Current portion of unrecognized tax benefits -- 6.8
Current portion of deferred tax liabilities -- 0.2
Current portion of deferred income 0.2 0.3
Total current liabilities 121.4 155.6
     
Long-term debt, net of current portion 115.0 142.7
Plant closure provisions, net of current portion 27.4 26.2
Unrecognized tax benefits, net of current portion 5.9 6.2
Deferred tax liabilities, net of current portion 10.8 9.5
Pension liabilities 29.2 39.0
Acquisition-related contingent consideration 4.9 4.6
Other non-current liabilities 1.5 0.3
Deferred income, net of current portion 1.0 1.2
Total stockholders' equity 457.5 409.4
Total liabilities and stockholders' equity  $ 774.6  $ 794.7
     
     
Schedule 4
     
INNOSPEC INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
     
  Nine Months Ended
  September 30
(in millions) 2014 2013
     
Cash Flows from Operating Activities    
     
Net income  $ 56.2  $ 49.1
Adjustments to reconcile net income to cash provided by operating activities:    
Depreciation and amortization 21.1 13.4
Impairment of Octane Additives segment goodwill -- 1.0
Deferred taxes 1.9 0.9
Repayment of promissory note in civil complaint settlement (5.0) (5.0)
Changes in working capital (15.4) (15.6)
Excess tax benefit from stock-based payment arrangements (0.7) (2.9)
Accrued income taxes 10.7 (5.3)
Movement on plant closure provisions (0.7) 0.6
Cash contributions to defined benefit pension plans (8.8) (8.1)
Non-cash expense of defined benefit pension plans 3.0 2.6
Stock option compensation 1.7 1.9
Movements on unrecognized tax benefits (7.2) (0.3)
Movements on other non-current assets and liabilities 2.2 (0.5)
Net cash provided by operating activities 59.0 31.8
     
Cash Flows from Investing Activities    
     
Capital expenditures (9.5) (6.6)
Business combinations, net of cash acquired 0.3 (50.6)
Internally developed software and other costs (6.1) (9.0)
Proceeds on disposal of property, plant and equipment 0.2 0.1
Purchase of short-term investments (4.2) (5.3)
Sale of short-term investments 5.8 4.1
Net cash used in investing activities (13.5) (67.3)
     
Cash Flows from Financing Activities    
     
Net (repayment)/receipt of revolving credit facility (27.0) 68.0
Repayment of term loans (0.9) --
Refinancing costs (0.1) (0.7)
Excess tax benefit from stock-based payment arrangements 0.7 2.9
Dividend paid (6.6) --
Issue of treasury stock 0.4 0.7
Repurchase of common stock (0.9) (3.7)
Net cash (used in)/provided by financing activities (34.4) 67.2
Effect of foreign currency exchange rate changes on cash (0.9) (0.2)
Net change in cash and cash equivalents 10.2 31.5
Cash and cash equivalents at beginning of period 80.2 22.4
Cash and cash equivalents at end of period  $ 90.4  $ 53.9
     
Amortization of deferred finance costs of $0.5million (2013 - $0.3million) are included in depreciation and amortization in the cash flow statement but in interest expense in the income statement.
     

Brian Watt Innospec Inc. +44-151-356-6241 Robert D. Ferris RF|Binder Partners +1-212-994-7505 Dan Scorpio RF|Binder Partners +1-212-994-7609

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading